Evidence map›Paper›PMID 31008021›Full record

ArticleCurrent molecular biology reports2019

FGF23 Synthesis and Activity.

Megan L Noonan, Kenneth E White

Abstract read
In one paragraph

Article in Current molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Emerging concepts on the FGF23 regulation and activity.Molecular and cellular biochemistry · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. A novel frameshift mutation inFrontiers in genetics · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Megan L NoonanDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Kenneth E WhiteDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.

Funding

BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASEST32HL007910 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Roland W. Herzog, Reuben Kapur · 1999 to 2026
$7.6M
Control of FGF23 Bioactivity via Circulating alpha-KlothoR01DK095784 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2013 to 2017
$1.7M
Novel Control of FGF23 in Metabolic Bone DiseaseR01DK112958 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2018 to 2020
$698k
Novel mediators of FGF23 bioactivityR21AR070329 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2016 to 2017
$381k
Conditional Isolation of Fgf23 ActivityR21AR059278 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2010 to 2011
$373k
NHLBI NIH HHS T32 HL007910NIAMS NIH HHS R21 AR059278NIAMS NIH HHS R21 AR070329NIDDK NIH HHS R01 DK095784NIDDK NIH HHS R01 DK112958
6 · The paper itself

Abstract

purpose of reviewThe phosphaturic hormone FGF23 is produced primarily in osteoblasts/osteocytes and is known to respond to increases in serum phosphate and 1,25(OH) RECENT

findingsThe synthesis of FGF23 in response to 1,25D is similar to other steroid hormone targets, but the cellular responses to phosphate remain largely unknown. The activity of intracellular processing genes control FGF23 glycosylation and phosphorylation, providing critical functions in determining the serum levels of bioactive FGF23. The actions of FGF23 largely occur through its co-receptor αKlotho (KL) under normal circumstances, but FGF23 has KL-independent activity during situations of high concentrations. SUMMARY: Recent work regarding FGF23 synthesis and bioactivity, as well as considerations for diseases of altered phosphate balance will be reviewed.

Indexed as

FAM20CFGF23Fibroblast growth factor-23FurinGALNT3KlothoosteomalaciaphosphatePSC3PTHricketsvitamin D

Identifiers

PMID31008021
PMCPMC6469709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.